Lab Dom Launches Its First Regenerative Medicine Educational Conference in Middle East

By Laboratoires Dom Avmm suisse Inc., PRNE
Wednesday, October 12, 2011

BEIRUT, Lebanon, October 13, 2011 -

Features seminars on the latest innovations in the field from leading UAE and European medical and scientific experts

Laboratoires Dom AVMM (Suisse) Inc., (Lab Dom) — a world-leading regenerative medicine and cellular therapy company — will hold its inaugural educational seminar for Middle East medical practitioners and aesthetic clinicians at the Four Season Hotel in Beirut, Lebanon on 14-15 October 2011.

The ‘1st Middle East Physician Educational Program on Swiss Cells Organotherapy and Stem Cell Therapy’ will be headlined by Switzerland’s Dr Olaf Kuhnke - President and Chairman of ZAEN, Europe’s largest academic organisation for the practice and control of complementary medicines — and will also feature the United Arab Emirate’s expert on precursor stem cell therapy treatments, Dr Dhafer Al-Gerrah.

“Given that world regenerative medicine revenues are expected to reach US$8.84bn by 2021 (Note), and that the Middle East expects to play a pivotal role in stem cell research and development, we believed the time was right to establish a key presence in this energetic and thought-leading market,” said Mike Chan, Co-founder, Laboratoires Dom AVMM (Suisse) Inc.

Presentations during the Lab Dom two-day educational training program in Beirut will be given by the company’s panel of international medical and scientific advisors, including; Dr Olaf Kuhnke (Switzerland); Dr Dhafer Al-Gerrah (UAE); Dr Rebekka Zirbel (Germany) and Claus-Peter Cremer (Germany). Successful case studies will focus on the use of Lab Dom’s precursor stem cell and organ-specific cell therapy products — MFIII of Switzerland and FCTI — for the treatment of chronic and degenerative diseases, as well as active-specific immunotherapy treatments for cancer.

Dr Dhafer Al-Gerrah from Abu Dhabi, UAE will present on the effective proven applications of precursor stem cell therapy for chronic aging, genetic, metabolic and chromosomal diseases using recent successful case studies in the treatment of autism and Down’s Syndrome.

“Lab Dom is currently poised to embark on an ambitious plan of global expansion, and we are hosting our first medical educational seminar in the Middle East specifically to open our doors for new preferred partners and associates to join us on our journey, share the bounty of our science and to grow with our new business,” stated Chan.

A well-respected pioneer at the forefront of the new era dawning in the global regenerative medicine and cellular therapy fields, Lab Dom is committed to continual evolution and change — both with the development of its cellular therapy products and as an organisation.

Lab Dom recently launched its dedicated ‘Change, with Lab Dom’ stakeholder campaign at the 7th European Masters in Aesthetic and Anti-Aging Medicine (EMAA 2011) exhibition, held in Paris, France in September this year. This campaign is aimed at servicing stakeholders and customers around the globe at a world’s best-practice level, and incorporates an innovative distribution model and a channel activation program.

“We are a family company, with family values, servicing a very human business. This is an unparalleled opportunity for partners to join us on our dynamic journey of expansion, and we invite interested practitioners and aesthetic clinicians in the Middle East to join us, and change with Lab Dom,” continued Chan.

Lab Dom’s exclusive Swiss Cellular Treatment programs held in Switzerland will also be a key feature introduced to the Middle East market during the two-day seminar program in Beirut. The company’s ‘Six Day, Six Star’ anti-aging and revitalisation program and the three-day ‘Executive Revitalisation Retreat’ are conducted at the MFIII / Orthobiomed Centre de Revitalisation in Roveredo, Switzerland and receive existing significant interest from the European and Chinese markets.

“With Switzerland, the traditional summer escape for many from the Middle East, we thought it is timely to introduce our Swiss cellular therapy treatment programs to the market and promote the opportunity to regenerate, revitalise and reinvigorate while holidaying in one of the most stunning and inspiring regions of the world,” said Michelle Wong, Co-founder, Laboratoires Dom AVMM (Suisse) Inc.

“We are in the business of providing the opportunity for change for humankind, and an opportunity to increase the quality of life itself.”

From 2012, Lab Dom will be introducing new levels of scientific and corporate governance, security, anti-fraud and counterfeit protection to take the industry lead on developments in the rapidly emerging regenerative medicine and cellular therapy fields.

The Beirut medical conference marks the second international event, in a series of six, that Lab Dom is participating in to create awareness of its new ‘Change, with Lab Dom’ stakeholder campaign, aimed at servicing stakeholders and customers around the globe at a world’s best-practice level which will be officially launched at a high-profile event in Las Vegas in December 2011.

About Lab Dom

Laboratoires Dom AVMM (Suisse) Inc., (Lab Dom) is a Swiss held and globally headquartered regenerative medicine and cellular therapy company, with regional Asia-Pacific headquarters in Kota Kinabalu, Malaysia.

Founded in 1998 by entrepreneurial husband and wife team, Mike Chan and Michelle Wong, Lab Dom is a world-leader in precursor stem cell, organ-specific cell, placental extracts and botanical cell product manufacturing and distribution, providing rejuvenation and revitalisation therapies to combat aging and chronic degenerative diseases.

With state-of-the-art laboratories and highly professional medical staff based in Switzerland, as well as the European Union and Asia-Pacific, Lab Dom is committed to innovative research and development in the rapidly expanding fields of regenerative medicine and anti-aging cellular therapy fields.

Lab Dom is currently embarking on a dynamic global expansion phase, aimed at increasing its presence in China, the European Union, the Middle East as well as the North and South American markets.

Note: Translational Regenerative Medicine: Market Prospects 2011-2021, published by visiongain, UK - July 2011

For media inquiries contact:

Andrew Tham
Message Manager
Lab Dom
Tel: +60-88-766266
Mobile: +60-16-8105490


Pharmaceuticals News

October 13 News

will not be displayed